The activity of a novel mithramycin analog is related to its binding to DNA, cellular accumulation, and inhibition of Sp1-driven gene transcription

Chemico-Biological Interactions

Volumn 219, Issue , 2014, Pages 123-132

  Fernández Guizán, Azahara ^a   Mansilla, Sylvia ^b   Barceló, Francisca ^c   Vizcaíno, Carolina ^b   Núñez, Luz Elena ^d   Morís, Francisco ^d   González, Segundo ^a   Portugal, José ^b  

^a DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^b INSTITUT DE BIOLOGIA MOLECULAR DE BARCELONA   (Spain)

^c UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^d EntreChem SL   (Spain)

Author keywords

Cell Uptake; DNA binding; Mithramycin; Ovarian cancer; Transcription

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DEMYCAROSYL 3 DEXTRO BETA DEXTRO DIGITOXOSYLMITHRAMYCIN SK; EC 8042; MITHRAMYCIN A; MITHRAMYCIN SK; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; DEMYCAROSYL-3D-DIGITOXOSYLMITHRAMYCIN SK; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MITHRAMYCIN; RNA; SIGNAL PEPTIDE; ULBP1 PROTEIN, HUMAN;

ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; DOWN REGULATION; DRUG ACCUMULATION; DRUG DNA BINDING; DRUG STRUCTURE; DRUG UPTAKE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; OVARIAN CANCER CELL LINE; SP1 GENE; ANALOGS AND DERIVATIVES; BINDING SITE; CHEMISTRY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; KINETICS; OVARIAN NEOPLASMS; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SPECTROFLUOROMETRY; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; BINDING SITES; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KINETICS; OVARIAN NEOPLASMS; PLICAMYCIN; REAL-TIME POLYMERASE CHAIN REACTION; RNA; SP1 TRANSCRIPTION FACTOR; SPECTROMETRY, FLUORESCENCE; TRANSCRIPTION, GENETIC;

EID: 84902687249     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2014.05.019     Document Type: Article

References (37)

1. F. Lombó, N. Menéndez, J.A. Salas, and C. Méndez The aureolic acid family of antitumor compounds: structure, mode of action, biosynthesis, and novel derivatives Appl. Microbiol. Biotechnol. 73 2006 1 14 (Pubitemid 44627719)
2. V.T. DeVita Jr., S. Hellman, and S.A. Rosenberg Cancer: Principles & Practice of Oncology 7th ed. 2005 Lippincott Williams & Wilkins Philadelphia, PA
3. P.D. King, and M.C. Perry Hepatotoxicity of chemotherapy Oncologist 6 2001 162 176 (Pubitemid 32323455)
4. L.L. Remsing, A.M. González, M. Nur-e-Alam, M.J. Fernández-Lozano, A.F. Braña, U. Rix, M.A. Oliveira, C. Méndez, J.A. Salas, J. Rohr, and S.K. Mithramycin A novel antitumor drug with improved therapeutic index, mithramycin SA, and demycarosyl-mithramycin SK: three new products generated in the mithramycin producer Streptomyces argillaceus through combinatorial biosynthesis J. Am. Chem. Soc. 125 2003 5745 5753 (Pubitemid 36592899)
5. M. Sastry, and D.J. Patel Solution structure of the mithramycin dimer-DNA complex Biochemistry 32 1993 6588 6604 (Pubitemid 23217128)
6. A.J. Hampshire, and K.R. Fox The effects of local DNA sequence on the interaction of ligands with their preferred binding sites Biochimie 90 2008 988 998
7. F. Barceló, C. Scotta, M. Ortiz-Lombardía, C. Méndez, J.A. Salas, and J. Portugal Entropically-driven binding of mithramycin in the minor groove of C/G-rich DNA sequences Nucleic Acids Res. 35 2007 2215 2226 (Pubitemid 47073709)
8. D.E. Jones Jr., D.M. Cui, and D.M. Miller Expression of β-galactosidase under the control of the human c-myc promoter in transgenic mice is inhibited by mithramycin Oncogene 10 1995 2323 2330
9. Z. Jia, J. Zhang, D. Wei, L. Wang, P. Yuan, X. Le, Q. Li, J. Yao, and K. Xie Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A Cancer Res. 67 2007 4878 4885 (Pubitemid 46910196)
10. D. Rodríguez, L.M. Quirós, and J.A. Salas MtmMII-mediated C-methylation during biosynthesis of the antitumor drug mithramycin is essential for biological activity and DNA-drug interaction J. Biol. Chem. 279 2004 8149 8158 (Pubitemid 38294706)
11. M. Pérez, I. Baig, A.F. Braña, J.A. Salas, J. Rohr, and C. Méndez Generation of new derivatives of the antitumor antibiotic mithramycin by altering the glycosylation pattern through combinatorial biosynthesis ChemBioChem 29 2008 2295 2304
12. B. García, J. González-Sabin, N. Menéndez, A.F. Braña, L.E. Nuñez, F. Morís, J.A. Salas, and C. Méndez The chromomycin CmmA acetyltransferase: a membrane-bound enzyme as a tool for increasing structural diversity of the antitumour mithramycin Microb. Biotechnol. 4 2011 226 238
13. L.E. Núñez, S.E. Nybo, J. González-Sabín, M. Pérez, N. Menéndez, A.F. Braña, M. He, F. Morís, J.A. Salas, J. Rohr, and C. Méndez A novel mithramycin analogue with high antitumor activity and less toxicity generated by combinatorial biosynthesis J. Med. Chem. 55 2012 5813 5825
14. A. Malek, L.E. Nuñez, M. Magistri, L. Brambilla, S. Jovic, G.M. Carbone, F. Moris, and C.V. Catapano Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer PLoS One 7 2012 e35130
15. S. Mansilla, I. Garcia-Ferrer, C. Méndez, J.A. Salas, and J. Portugal Differential inhibition of restriction enzyme cleavage by chromophore-modified analogues of the antitumour antibiotics mithramycin and chromomycin reveals structure-activity relationships Biochem. Pharmacol. 79 2010 1418 1427
16. F. Barceló, M. Ortiz-Lombardía, M. Martorell, M. Oliver, C. Méndez, J.A. Salas, and J. Portugal DNA binding characteristics of mithramycin and chromomycin analogues obtained by combinatorial biosynthesis Biochemistry 49 2010 10543 10552
17. V. Albertini, A. Jain, S. Vignati, S. Napoli, A. Rinaldi, I. Kwee, M. Nur-e-Alam, J. Bergant, F. Bertoni, G.M. Carbone, J. Rohr, and C.V. Catapano Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy Nucleic Acids Res. 34 2006 1721 1734
18. S. Previdi, A. Malek, V. Albertini, C. Riva, C. Capella, M. Broggini, G.M. Carbone, J. Rohr, and C.V. Catapano Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts Gynecol. Oncol. 118 2010 182 188
19. M. Bataller, C. Méndez, J.A. Salas, and J. Portugal Mithramycin SK modulates polyploidy and cell death in colon carcinoma cells Mol. Cancer Ther. 7 2008 2988 2997
20. C. Vizcaíno, S. Mansilla, L.E. Núñez, C. Méndez, J.A. Salas, F. Morís, and J. Portugal Novel mithramycins abrogate the involvement of protein factors in the transcription of cell cycle control genes Biochem. Pharmacol. 84 2012 1133 1142
21. S. Safe, and M. Abdelrahim Sp transcription factor family and its role in cancer Eur. J. Cancer 41 2005 2438 2448 (Pubitemid 41540621)
22. I. Wierstra Sp1: emerging roles - beyond constitutive activation of TATA-less housekeeping genes Biochem. Biophys. Res. Commun. 372 2008 1 13
23. M. Zhang, A. Mathur, Y. Zhang, S. Xi, S. Atay, J.A. Hong, N. Datrice, T. Upham, C.D. Kemp, R.T. Ripley, G. Wiegand, I. Avital, P. Fetsch, H. Mani, D. Zlott, R. Robey, S.E. Bates, X. Li, M. Rao, and D.S. Schrump Mithramycin represses basal and cigarette smoke-Induced expression of ABCG2 and inhibits stem cell signaling in lung and esophageal cancer cells Cancer Res. 72 2012 4178 4192
24. S. Su, and C.J. Omiecinski Sp1 and Sp3 transcription factors regulate the basal expression of human microsomal epoxide hydrolase (EPHX1) through interaction with the E1b far upstream promoter Gene 536 2014 135 144
25. G. Suske The Sp-family of transcription factors Gene 238 1999 291 300 (Pubitemid 29446168)
26. A. López-Soto, A. Quiñones-Lombrana, R. López-Arbesu, C. López-Larrea, and S. González Transcriptional regulation of ULBP1, a human ligand of the NKG2D receptor J. Biol. Chem. 281 2006 30419 30430 (Pubitemid 44582098)
27. A. López-Soto, A.R. Folgueras, E. Seto, and S. González HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer Oncogene 28 2009 2370 2382
28. R.W. McGilvray, R.A. Eagle, P. Rolland, I. Jafferji, J. Trowsdale, and L.G. Durrant ULBP2 and RAET1E NKG2D ligands are independent predictors of poor prognosis in ovarian cancer patients Int. J. Cancer 127 2010 1412 1420
29. A.D. Malcolm, and J.R. Moffatt Differential reactivities at restriction enzyme sites Biochim. Biophys. Acta 655 1981 128 135
30. P.M. Yang, P.J. Lin, and C.C. Chen CD1d induction in solid tumor cells by histone deacetylase inhibitors through inhibition of HDAC1/2 and activation of Sp1 Epigenetics 7 2012 390 399
31. WAF1-deficient HCT116 human colon carcinoma cells Cancer Lett. 292 2010 80 90
32. L.L. Remsing, H.R. Bahadori, G.M. Carbone, E.M. McGuffie, C.V. Catapano, and J. Rohr Inhibition of c-src transcription by mithramycin: structure-activity relationships of biosynthetically produced mithramycin analogues using the c-src promoter as target Biochemistry 42 2003 8313 8324 (Pubitemid 36858992)
33. P.D. Grivas, H. Kiaris, and A.G. Papavassiliou Tackling transcription factors: challenges in antitumor therapy Trends Mol. Med. 17 2011 537 538
34. V.A. Bloomfield, D.M. Crothers, and I. Tinoco Jr. Physical Chemistry of Nucleic Acids 1974 Harper & Row New York p. 436
35. S. Mansilla, and J. Portugal Sp1 transcription factor as a target for anthracyclines: effects on gene transcription Biochimie 90 2008 976 987
36. Y.A. Boumber, Y. Kondo, X. Chen, L. Shen, Y. Guo, C. Tellez, M.R. Estecio, S. Ahmed, and J.P. Issa An Sp1/Sp3 binding polymorphism confers methylation protection PLoS Genet. 4 2008 e1000162
37. S.N. Westin, T.J. Herzog, and R.L. Coleman Investigational agents in development for the treatment of ovarian cancer Invest. New Drugs 31 2013 213 229.